13 April 2021
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.
1 April 2021
'Live' measurements of cell signals show need for combination therapy in colorectal cancer
The team of Oncode Investigator Hugo Snippert (UMC Utrecht) has succeeded in using organoid technology to monitor live how a colon tumor responds to a combination therapy. The results appear today, April 1st, in the leading journal Nature Cell Biology.
23 March 2021
Recent developments in single-cell genomics/epigenomics: highlights from this year’s first Masterclass
Advances in single-cell technologies are providing unprecedented opportunities to analyse the complexities of biological systems at exceptional resolutions. They provide means to gain a better understanding of diverse processes such as tumorigenesis, gene expression dynamics and tumour heterogeneity. In a masterclass organised via Zoom at the beginning of this year, Oncode Investigator Jop Kind and 7 other speakers, familiarized attendees with the field of single-cell genomics/epigenomics and its applications, including a virtual tour of the new single cell epigenomics facility.
In the spotlight
22 July 2020
COVID-19: updates for the Oncode research community
As an Oncode researcher, you might have questions about how we are mitigating the impact of the current COVID-19 crisis on our programmes, projects and funding. We created a Q&A with the answers these questions and plan to update this Q&A regularly.
10 March 2021
Oncode Investigator Jarno Drost co-leads research that unravels the origin of a form of childhood cancer
Malignant rhabdoid tumor (MRT) is a rare type of childhood cancer. Its origins have been unknown until now. A recently published paper in Nature Communications, co-led by Oncode Investigator Jarno Drost in collaboration with researchers at Wellcome Sanger Institute unravels its origins. Beyond that, the study also identifies two drugs to fight it.
9 March 2021
Oncode Investigator Louis Vermeulen wins the prestigious Ammodo Science Award 2021
Oncode Investigator Louis Vermeulen (Amsterdam UMC) studies how derailments in the genetic material of stem cells can cause colon cancer, and focuses specifically on the earliest development of tumors. He combines biochemistry and genetics with mathematical and physical models to map the dynamics of stem cells. Because he is not afraid to venture outside the beaten path, his innovative approach has made a major contribution to fundamental concepts within molecular oncology. This is why he is amongst the eight outstanding mid-career scientists working in the Netherlands awarded this year’s Ammodo Science Award.
23 February 2021
License signed: Oncode successfully mediates agreement for innovative algorithm RAINFOREST
Oncode’s valorization team at work: we are happy to announce that SkylineDx has signed a license agreement with Oncode Institute and Utrecht Holdings on a shared patent covering the innovative algorithm RAINFOREST.
4 February 2021
‘De vleugels van de wetenschap' - een verhaal over fundamenteel onderzoek met levens veranderende impact
- Dutch translation of the English article - Wat hebben de Nederlandse onderzoeker en Oncode Investigator Rene Bernards (NKI) en de Britse columniste en podcaster Deborah James met elkaar gemeen? Ze zijn beiden op een missie om kanker te bestrijden. Bernards ultieme doel is om zijn onderzoeksresultaten naar de kliniek te vertalen en daarmee impact te hebben op het leven van mensen. James veranderde de diagnose stadium 4 darmkanker in een missie, niet alleen om de ziekte te bestrijden, maar ook om het gesprek erover te veranderen. De twee ontmoetten elkaar in 2018: toen James geen behandelingsopties meer had, was het Bernards innovatieve therapie die haar te hulp schoot.
Scroll for more